No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - General
JCR Pharmaceuticals Co., Ltd. is a specialized pharmaceutical firm primarily engaged in the creation, development, manufacturing, international trade, and distribution of medicinal products, regenerative therapies, and active pharmaceutical ingredients within Japan. The company offers a range of therapeutic solutions, including GROWJECT, which addresses growth hormone deficiency and short stature; IZCARGO, prescribed for Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion, utilized in the management of Fabry disease; and TEMCELL HS Inj, employed to treat acute graft-versus-host disease. Beyond its current offerings, JCR Pharmaceuticals is also developing Epoetin Alfa BS and Darbepoetin Alfa BS Injections, both intended for the treatment of renal anemia. Furthermore, the company markets various medical devices and laboratory instruments. Founded in 1975, its headquarters are situated in Ashiya, Japan.
www.jcrpharm.co.jpNo one on the platform currently holds 4552.T.
No tracked institution reports a position in 4552.T as of their last filing.
No one on the platform has traded 4552.T yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 0.3% | — | — | — | ||
| Rev. Growth % | 21.9% | 6.0% | ||||
| Profit Margin % | 5.4% | 8.7% | 11.8% | |||
| Free Cash Flow Margin % | -28.7% | -19.9% | -5.1% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $44.2B | +13.6% | $3.01 | $0.87–$5.96 | — | 5 |
| 2028 | $41.6B | -5.9% | $3.01 | $-2.92–$8.31 | — | 5 |
| 2029 | $42.5B | +2.1% | $10.66 | $-0.50–$22.38 | — | 5 |
| 2030 | $46.0B | +8.2% | $23.55 | $18.27–$25.94 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-30 | $-11.27 | $-15.64 | -38.8% |
| 2026-05-13 | $-6.63 | $3.57 | +153.9% |
| 2026-01-28 | $-1.07 | $0.27 | +125.2% |
| 2025-10-30 | $20.39 | $18.51 | -9.2% |
| 2025-07-30 | $4.36 | $-4.48 | -202.8% |
| 2025-05-13 | $-53.70 | $-33.80 | +37.1% |
| 2025-01-31 | $9.49 | $0.90 | -90.5% |
| 2024-10-30 | $15.27 |
| $-7.14 |
| -146.8% |
| -1.73% |
| $71.5B |
| — |
| 4549.TEiken Chemical Co., Ltd. | $2260.00 | +0.22% | $74.5B | — |
| 4559.TZeria Pharmaceutical Co., Ltd. | $2014.00 | -0.10% | $88.8B | — |
Source: Financial Modeling Prep · peers by sector/industry